Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

On location

PI3K Inhibitors Safe and Effective in CLL Patients

Updated data on the safety and effectiveness of three different phosphoinositide 3-kinase inhibitors (PI3K inhibitors) presented at the European Hematology Association (EHA) Congress show...
On location

Single-Agent Ibrutinib Leads to Durable Responses in CLL

In both treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), single-agent ibrutinib led to durable responses, according to...
On location

Pediatric Leukemia Patients May Benefit from CAR Therapy

Genetically reprogrammed T cells, which have been making waves in adult acute lymphocytic leukemia (ALL), have also shown promise in pediatric ALL patients, according...
On location

Updates on Novel Treatments for Leukemia

Three sessions at the American Association for Cancer Research Annual Meeting focused on promising, novel treatment options for patients with various forms of leukemia. In...
On location

Study Evaluates Safety of Cytotoxic T Lymphocytes for Rituximab-Refractory Epstein-Barr Virus

For patients who have undergone stem cell or organ transplantation, the drugs administered to prevent organ rejection can weaken the immune system, which can...
On location

IOM/ACS Pediatric Oncology Workshop Highlights Survivorship Issues

On March 9-10, the Institute of Medicine’s (IOM’s) National Cancer Policy Forum (NCPF) and the American Cancer Society (ACS) sponsored a workshop on Comprehensive...
On location

Great Strides in Survivorship of Childhood Cancer Since the 1970s

More refined treatment and modern screening methods have led to improved long-term survival rates for children and young adults diagnosed with cancer – particularly...
On location

Ibrutinib Well Tolerated in Patients With Central Nervous System Lymphoma

CHICAGO--With few treatment options available for central nervous system lymphoma (CNSL), patients with recurrent/refractory disease typically have poor outcomes, with response rates ranging between...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.